Expert Interview
A Third Look: Discussing the potential of JNJ-1802, a first-in-class oral antiviral in development by Johnson & Johnson for the prevention of dengue fever.
Ticker(s): JNJInstitution: Western Michigan University Homer Stryker M.D. School of Medicine
- Assistant Professor in the Department of Medicine and in the Division of Infectious Disease.
- treats 8 patients per year with invasive fungal infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and pulmonary invasive aspergillosis (IA)
- familiar with Olorofim and the interim results from the Phase 2b study(NCT03583164)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
